Stone Man Syndrome: Unraveling The Layers of A Rare Genetic Disorder

Progressive heterotopic ossification [HO] of soft connective tissues, such as muscles, tendons, and ligaments, is a hallmark of fibrodysplasia ossificans progressiva [FOP], popularly known as "Stone Man Syndrome," an incredibly rare autosomal dominant genetic condition. A gain-of-function mutation in the activin A receptor type 1 [ACVR1] gene, most frequently R206H, induces constitutive activation of the bone morphogenetic protein [BMP] signaling pathway, even in the absence of ligands, leading to this crippling illness. Congenital abnormalities of the great toes are the usual early childhood manifestation of FOP, frequently occurring before flare-ups that result in progressive immobility and disability. Clinical presentation, radiologic imaging, and confirming genetic tests are all necessary for the diagnosis. The condition is often misdiagnosed due to its rarity and complexity, which delays necessary early care. No curative therapy currently exists; management focuses on minimizing trauma, avoiding intramuscular procedures, and controlling flare-ups with corticosteroids. Surgical intervention is limited to select cases and must be approached with caution due to risk of further ossification. Ongoing research into ACVR1 inhibition and BMP pathway modulation holds promise for disease-modifying treatments. This review aims to consolidate current understanding of FOP’s genetic basis, clinical presentation, diagnostic approach, and evolving management strategies to improve outcomes in this challenging and life-limiting disorder.